Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Cash from Operations (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Cash from Operations for 9 consecutive years, with 7153000.0 as the latest value for Q4 2024.

  • Quarterly Cash from Operations fell 48.25% to 7153000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 35402000.0 through Dec 2024, down 12.71% year-over-year, with the annual reading at 28400000.0 for FY2025, 19.78% up from the prior year.
  • Cash from Operations for Q4 2024 was 7153000.0 at SELLAS Life Sciences, up from 7806000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 3424000.0 in Q4 2020, with the low at 12127000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 6352950.0, with a median of 6354500.0 recorded in 2020.
  • The sharpest move saw Cash from Operations crashed 245.33% in 2021, then surged 30.37% in 2022.
  • Over 5 years, Cash from Operations stood at 3424000.0 in 2020, then plummeted by 245.33% to 4976000.0 in 2021, then dropped by 3.54% to 5152000.0 in 2022, then grew by 6.35% to 4825000.0 in 2023, then plummeted by 48.25% to 7153000.0 in 2024.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 7153000.0, 7806000.0, and 9682000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.